In a report released today, Joseph Stringer from Needham maintained a Buy rating on Alnylam Pharma (ALNY – Research Report), with a price target of $320.00.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Joseph Stringer has given his Buy rating due to a combination of factors that highlight Alnylam Pharma’s strong position in the market. The recent approval of Amvuttra for ATTR-CM is a significant milestone, indicating the company’s potential to capture a substantial market share in this area.
Furthermore, the discussions with key executives at the Needham Healthcare Conference revealed promising prospects for Amvuttra’s launch and its future in the market. Additionally, Alnylam’s robust pipeline, both within and outside the TTR space, underscores its capability for sustained growth and innovation, supporting the Buy rating.
In another report released on April 3, Canaccord Genuity also reiterated a Buy rating on the stock with a $390.00 price target.